Pocenbrodib is Pathos’ first clinical-stage asset in its pipeline. "The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in ...

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced ...

Two Tempus executives, including serial entrepreneur and billionaire Eric Lefkofsky, are behind a new drug discovery company in Chicago that's looking to raise $40 million. The startup, called Pathos ...